Pharma & Biotech

Neurocrine Biosciences shares are demonstrating remarkable resilience in a biotech sector often characterized by extreme volatility. The neuropharmaceutical company has...

The biotechnology sector remains a high-stakes environment, and Design Therapeutics currently embodies this volatility. Recent developments surrounding the company's innovative...

The biotechnology sector is inherently risky, but Nautilus Biotechnology appears to be pushing those risks to the extreme. A seemingly...

A significant liquidity event is unfolding for Cellectar Biosciences as a 61-day lock-up restriction on insider securities officially concludes. This...

Bruker Corporation, a leading manufacturer of analytical instrumentation, faces significant investor skepticism after reporting unexpectedly weak second-quarter 2025 results and...

Shares of BioNano Genomics closed Friday's session at $3.77, marking a modest decline of 2.08%. This slight pullback followed a...

Cyclacel Pharmaceuticals shares concluded Friday's exceptionally volatile trading session at $8.24, demonstrating a strong upward trajectory. The biotech equity is...

Shares of 908 Devices Inc. have continued their downward trajectory, marking a third consecutive day of losses despite the company...

BioNTech SE is executing a remarkable strategic transformation, evolving from its pandemic-era identity into a diversified biotechnology powerhouse. This shift...

Essa Pharma Inc. has initiated the final phase of its corporate wind-down, completing the previously announced transaction with XenoTherapeutics, Inc....